摘要
[目的]观察恩度联合EP方案治疗晚期小细胞肺癌的临床疗效.[方法]40例晚期小细胞肺癌患者随机分为两组,观察组20例行EP方案d1～14加15 mg/d恩度治疗,对照组的20例仅采用EP方案治疗,1个周期为21 d,治疗2周期后比较两组的治疗效果.[结果]观察组有效率为70%,对照组有效率为45%,两组相比较差异具有统计学意义（P〈0.05）,两组副反应发生率相比较差异无显著性.[结论]在EP方案治疗的基础上加恩度治疗小细胞肺癌疗效显著,而且不良反应较小,在同类药物中,其毒性较低且效果好.
[Objective]To observe the clinical efficacy of Endostar combined with EP scheme for the treat ment of advanced small cell lung cancer. [Methods] Forty patients with advanced small cell lung cancer were randomly divided into 2 groups. The observation group（ n = 20） additionally received 15mg/d Endostar treatment during the first 1-14 days of EP scheme. The control group（ n =20） received only EP scheme. The cy cle of treatment was 21 days. The efficacy at 2 weeks after treatment was compared between two groups. [Results] The effective rate of observation group and control group was 85% and 50% respectively, and there was significant difference between two groups（ P〈0.05）. There was no significant difference in the incidence of the adverse reaction between two groups. [Conclusion]Endostar based on EP scheme for the treatment of small cell lung cancer is significantly effective, and has less adverse reaction. Compared with the same kind of drugs, Endostar has lower toxicity and good effect.
出处
《医学临床研究》
CAS
2011年第2期257-258,共2页
Journal of Clinical Research
